AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05479994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally
Study NCT03813095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1501
Description: The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
Study NCT04100135 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device PFO closure
Description: Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
Study NCT03813095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
Study NCT06450041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal Donor (UD) TGFβi NK Cells
Description: Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
Study NCT06450041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
Study NCT06450041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/dose IV daily on days 1-5 of each cycle
Study NCT06450041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: 17.5mg/m2/dose IV daily on days 2-5 of each cycle
Study NCT06450041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
Study NCT05864807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCon
Description: The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
Study NCT04898647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fundoscopic picture
Description: A central review of numerised fundoscopic picture will be performed.
Study NCT04898647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fundoscopic picture
Description: A central review of numerised fundoscopic picture will be performed.
Study NCT04898647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling
Study NCT04898647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling
Study NCT04898647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow sample
Description: Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
Study NCT04898647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow sample
Description: Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
Study NCT05183191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving with a driving simulator
Description: Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
Study NCT04596670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-ICAM-1pep
Description: 68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Study NCT06411847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual appointments
Description: This group will receive the same information as the control group with additional virtual appointments at 1 week, 2 weeks and 6 weeks after fitting a Twin Block appliance. These will be scheduled and held via BlueEye Clinic (RedZinc Services Ltd.), a web-based GDPR compliant platform that allows patients to access a remote video consultation via a link sent to the participant/parent's device. The content of these appointments will follow a template that addresses the patient's experience, difficulties faced and how to overcome these, and would incorporate use of visual aids to highlight expected changes over the duration of wear. The appointments would be held in the late afternoons (after school).
Study NCT05734677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation group
Description: 90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
Study NCT05909085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ultrasound
Description: Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
Study NCT05909085 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Automated ultrasound
Description: Labor epidural will be performed after marking patient skin using an automated ultrasound device
Study NCT05487989 — intervention group
Intervention type: OTHER
Intervention: Clinical examen
Description: MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
Study NCT06208215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC
Description: Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
Study NCT06208215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RZ358 (10 mg/kg) or Placebo + SOC
Description: Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
Study NCT06208215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 (5-10 mg/kg) + SOC
Description: Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
Study NCT06558370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Empty bladder group
Description: Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
Study NCT06558370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder distension group
Description: Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
Study NCT05248711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Daily Move
Description: The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
Study NCT04883983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Placebo
Description: Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
Study NCT04883983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient medication as standardly prescribed
Description: Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
Study NCT06177808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-compliant balloon
Description: As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
Study NCT05056831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend face-to-face mind-body sessions
Study NCT05056831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05056831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive targeted text messages
Study NCT05056831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05056831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05056831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05056831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06498037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Administration of subcutaneously administered fentanyl loading boluses
Study NCT05813470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab (CinnaGen)
Description: Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
Study NCT05813470 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
Description: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
Study NCT05435430 — intervention group
Intervention type: OTHER
Intervention: PERSPECTIVE, MULTICENTRIC and observational
Description: we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
Study NCT04642235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Nook
Description: The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
Study NCT04642235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Coach
Description: The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach.
Study NCT04642235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Nook + Nature Coach
Description: The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
Study NCT05275114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS stimulation with hand task
Description: 30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
Study NCT05275114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS stimulation with hand task
Description: 30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
Study NCT06657066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii
Description: Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
Study NCT06657066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
Study NCT06656897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)
Description: FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
Study NCT06657677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40mg oral iron dosing
Description: Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
Study NCT06657677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100mg oral iron dosing
Description: Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
Study NCT06657677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 180mg oral iron dosing
Description: Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
Study NCT05294900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Description: Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5
Study NCT06143631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral letrozole 2.5mg/day
Study NCT06143631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Oral letrozole 2.5mg/day
Study NCT06143631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT06296264 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard ultrasound
Description: Placement of IV line using standard ultrasound.
Study NCT06296264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-portable ultrasound
Description: Placement of IV line using ultra-portable ultrasound.
Study NCT05895513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Description: 5HT-2a receptor antagonist
Study NCT05895513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Comparator
Study NCT04914897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Intravenous infusion: solution for infusion
Study NCT04914897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion: solution for infusion
Study NCT05091346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 tablet.
Study NCT05091346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.
Study NCT05091346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsule.
Study NCT06623981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Interpersonal Psychotherapy
Description: Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
Study NCT06623981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplemented Usual Care
Description: Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
Study NCT06443086 — intervention group
Intervention type: PROCEDURE
Intervention: Radical operation and perioperative therapy
Description: Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
Study NCT06267313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Training attention away from threat
Study NCT06267313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Training
Description: Training attention control
Study NCT06267313 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral training
Description: Attention training with Neutral stimuli
Study NCT04722458 — intervention group
Intervention type: OTHER
Intervention: Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)
Description: LURN SI-29
Study NCT04722458 — intervention group
Intervention type: OTHER
Intervention: IPSS
Description: International Prostate Symptom Score
Study NCT04772235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib
Study NCT04840667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REPLAGAL
Description: Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
Study NCT05780866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video and Activity Tracker
Description: At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study.
Study NCT04722458 — intervention group
Intervention type: OTHER
Intervention: UDI-6
Description: Urogenital Distress Inventory